Erasing cancer, reviving oncolytic virus, treating a rare neuromuscular condition: Here’s what you need to know about the 5 new biotechs filing for IPOs

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

Last week was a busy one for biotech IPOs, with five more companies filing to go public just before the start of the weekend, including a company led by GlaxoSmithKline vet Paul Peter...

Click to view original post

Erasing cancer, reviving oncolytic virus, treating a rare neuromuscular condition: Here’s what you need to know about the 5 new biotechs filing for IPOs

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

Last week was a busy one for biotech IPOs, with five more companies filing to go public just before the start of the weekend, including a company led by GlaxoSmithKline vet Paul Peter...

Click to view original post